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In the human body, the complex biochemical network known as the mevalonate pathway
is responsible for the biosynthesis of all isoprenoids, which consists of a vast array of
metabolites that are vital for proper cellular functions. Two key isoprenoids, farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) are responsible for the
post-translational prenylation of small GTP-binding proteins, and serve as the biosynthetic
precursors to numerous other biomolecules. The down-stream metabolite of FPP and
GGPP is squalene, the precursor to steroids, bile acids, lipoproteins, and vitamin D. In
the past, interest in prenyl synthase inhibitors focused mainly on the role of the FPP in
lytic bone diseases. More recently pre-clinical and clinical studies have strongly implicated
high levels of protein prenylation in a plethora of human diseases, including non-skeletal
cancers, the progression of neurodegenerative diseases and cardiovascular diseases. In
this review, we focus mainly on the potential therapeutic value of down-regulating the
biosynthesis of FPP, GGPP, and squalene. We summarize the most recent drug discovery
efforts and the structural data available that support the current on-going studies.
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INTRODUCTION
The mevalonate pathway is responsible for biosynthesis of all
mammalian isoprenoids (Figure 1). These metabolites are essen-
tial for the post-translational prenylation of small GTP-binding
proteins and serve as precursors to numerous other biomolecules,
including cholesterol (which is essential for the integrity of cell
membranes and is the precursor to all mammalian steroids, bile
acids, lipoproteins, and vitamin D), haem A and ubiquinone
(which are involved in electron transport), dolichol (essential
for glycoprotein synthesis), and isopentenyladenine (found in
tRNAs) (Goldstein and Brown, 1990).
The rate-limiting step of the mevalonate pathway is catalyzed
by hydroxymethylglutaryl coenzyme A reductase (HMC-CoA),
leading to the formation of mevalonic acid. This metabolite is
the immediate precursor of the 5-carbon isoprenoid monomer
unit, isopentenyl pyrophosphate (IPP), and its isomer dimethy-
lallyl pyrophosphate (DMAPP; Figure 2). Numerous reports have
been written about HMG-CoA reductase as a therapeutic target
and the value of the statin family of inhibitors in the treat-
ment of atherosclerosis (Endo, 1992). Therefore, this account will
focus mainly on the three down-stream prenyl synthase enzymes,
the human farnesyl pyrophosphate synthase (hFPPS), geranylger-
anyl pyrophosphate synthase (hGGPPS), and squalene synthase
(hSQS). Based on pre-clinical and clinical data, the potential value
of these enzymes in drug discovery will be discussed. The current
state of the art in the design of inhibitors and the structural inves-
tigations that provide insight into the mechanisms of action of
these inhibitors will also be described.
The first branching point of the mevalonate pathway is occu-
pied by farnesyl pyrophosphate synthase (FPPS), the enzyme
responsible for the catalytic elongation of DMAPP first to ger-
anyl pyrophosphate (GPP) and then to FPP via the successive
condensation of two IPP units (Figure 2). FPP is the substrate
of geranylgeranyl pyrophosphate synthase (GGPPS), which cat-
alyzes the down-stream extension of the C-15 isoprenoid (FPP) to
the C-20 geranylgeranyl pyrophosphate (GGPP; Figure 2). Post-
translational modification of proteins with either FPP or GGPP
is estimated to constitute ∼2% of the total mammalian proteome
(Nguyen et al., 2009). Both FPP and GGPP are essential for the
prenylation of small GTP-binding proteins (GTPases), a family
of signaling proteins that are fundamentally important for cell
survival (Takai et al., 2001). Covalent attachment of the FPP or
GGPP lipid tail to a highly conserved cysteine residue at the CAAX
box motif near/or at the C-terminal of a GTPase protein (where
A is an aliphatic amino acid), confers membrane localization of
this protein, promotes specific interactions with other proteins
and plays a crucial role in controlling intracellular trafficking.
Farnesylation is predominant when X is a methionine, serine, cys-
teine, or a glutamine residue, whereas geranylgeranylation usually
occurs when X is leucine or isoleucine.
The known farnesylated proteins include members of the Ras
superfamily of GTPases (e.g., H-Ras, K-Ras, N-Ras) (Kho et al.,
2004), the precursor proteins of the nuclear lamin A (Young
et al., 2005; Chang et al., 2012), and members of the DnaJ chap-
erone proteins (Kampinga and Craig, 2010; Stark et al., 2014).
Geranylgeranylated GTPases include the Rho family of proteins,
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FIGURE 1 | Schematic representation of the mevalonate pathway,
indicating the major biochemical effects of isoprenoids. Classes of
current drugs that modulate the function of key enzymes include Statins and
Bisphosphonates (indicated — ). FPPS, GGPS, and SQS enzymes are
highlighted in green color boxes; other key enzymes are highlighted in gray
color boxes.
FIGURE 2 | Structures and sequence of steps involved in the biosynthesis of key isoprenoids.
such as RhoA/B/C, Rac-1, and Cdc42 (Figure 1). Interestingly,
the substrate specificity of the transferase enzymes which catalyze
the prenylation step, FTase, and GGTase I and II (Figure 1) is
not absolutely stringent and cross-prenylation has been observed
(Rowell et al., 1997; Whyte et al., 1997; Yokoyama et al., 1997;
Kho et al., 2004; Rowinsky, 2006). This redundancy mechanism
has been blamed for the failure of FTase inhibitors (e.g., tipi-
farnib) to demonstrate significant clinical efficacy in the intended
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treatments of pancreatic (90% K-Ras mutations), lung, and
colon carcinomas (∼30% K-Ras mutations) (Lerner et al., 1997;
Sparano et al., 2009).
OVERVIEW OF THE HUMAN FPPS, GGPPS, AND SQS AS
THERAPEUTIC TARGETS
HUMAN FPPS
For over 40 years, drug discovery efforts focused mainly on the
ability of hFPPS inhibitors to block osteoclast-mediated bone
resorption; a number of excellent review articles have been writ-
ten specifically on this topic (Dunford et al., 2001; Dunford,
2010; Ebetino et al., 2011; Russell, 2011). Currently, nitrogen-
containing bisphosphonate (N-BP) inhibitors of hFPPS are used
extensively to treat bone diseases, including osteoporosis, tumor-
induced hypercalcemia, Paget’s disease, and osteolytic cancer
metastases (Fournier et al., 2010).
Chemically, N-BPs are stable analogs of naturally occurring
pyrophosphates (diphosphates), such as inorganic pyrophos-
phate. At physiological pH, the bisphosphonate moiety is
assumed to be ionized to the trianion (based on a pKa for the
3rd ionization of ∼7.0) and further dissociates to the tetra anion
in the presence of the enzyme’s three co-factor Mg2+ ions. The
structure of the current N-BP drugs features a Cα-hydroxyl sub-
stituent, which modulates the pKa of the two phosphonates and
maximizes the affinity of these compounds for the bone mineral
hydroxyapatite (Marma et al., 2007; Jahnke and Henry, 2010).
N-BPs bind so avidly to bone that their half-life (in bone) can
be months to several years, depending on the type of drug used
and the disease affecting the rate of bone turnover (Grey et al.,
2009; Frost et al., 2012). In chronic diseases (e.g., osteoporo-
sis), concerns that prolonged use of high-dose N-BPs can cause
side effects, such as osteonecrosis of the jaw (ONJ) and atypical
femoral fractures (Rizzoli et al., 2008), have led to the recommen-
dation by physicians of a “drug holiday.” However, this treatment
can lead to uncertainty with respect to the type of drug and
dose to be used, as well as the duration of treatment for differ-
ent patients (Eastell et al., 2011). Although ONJ is uncommon
in patients treated for osteoporosis, it is a long-lasting disorder
that can occur in patients treated for bone cancer metastasis with
high doses of intravenous bisphosphonates (Hoff et al., 2008;
Dimopoulos et al., 2009; Ripamonti et al., 2009). The systemic
half-life of current N-BPs is extremely low; for example, after
i.v. administration of zoledronic acid (1a), 50% of the dose gets
trapped in the bone mineral and the rest is rapidly cleared by the
kidneys. In fact, the dose-limiting toxicity of N-BP drugs, is usu-
ally based on nephrotoxicity (Skerjanec et al., 2003; Weiss et al.,
2008). In spite of these limitations, N-BP drugs improve the qual-
ity of life for patients with lytic bone diseases; ∼1 out of every
2 post-menopausal women suffers from osteoporosis and ∼70%
of all breast, prostate and multiple myeloma patients will develop
bone metastases at some stage of their diseases. Currently, it is
estimated that 400,000 patients/year in the USA alone suffer from
lytic bone diseases due to cancer metastasis (Bagi, 2005; Coleman,
2006).
In addition to the skeletal benefits of N-BPs, recent pre-clinical
studies have shown that they can suppress the proliferation of var-
ious types of cancer cells, including prostate (Iguchi et al., 2010;
Mani et al., 2012), breast (Räikkönen et al., 2010; Dedes et al.,
2012), and colorectal (Notarnicola et al., 2004) cancers, human
glioblastoma (Cimini et al., 2011), and multiple myeloma (MM).
Higher expression of hFPPS has been observed in human prostate
cancer tissues (as compared to controls), suggesting an associ-
ation between prenylation and disease progression (Todenhöfer
et al., 2013). In the case of myeloma, a recent report of whole
genome sequencing of tumors from 38 MM patients demon-
strated that exactly 50% of these patients harbored either K-Ras
or N-Ras codingmutations, underscoring the importance of these
oncogenes in MM (Chapman et al., 2011). Clinical investiga-
tions have also provided evidence that some N-BP drugs (e.g., 1a)
improve the survival of patients with MM via mechanisms that
are both related, as well as unrelated to the skeletal benefits
(Morgan et al., 2010, 2012). Similar results have been reported for
patients with premenopausal breast cancer (Gnant et al., 2009),
although these findings seem to be more controversial (Coleman
et al., 2011). In spite of all the preliminary evidence, the limited
half-life of N-BPs in plasma (i.e., the fast elimination from the
blood circulation) and negligible distribution to non-skeletal tis-
sues compromise clinical validation of these compounds as true
antineoplastic agents, and consequently, the clinical validation of
hFPPS as a therapeutic target for non-skeletal malignancies.
To date, the observed N-BP-mediated anti-neoplastic effects
have been attributed to multiple mechanisms relating to a
plethora of biochemical processes that hFPPS controls (Figure 1).
These mechanisms include the direct down-regulation of preny-
lated/activated mutated Ras proteins, thus inhibiting growth
and/or survival of malignant cells. Inhibition of hFPPS also
impacts the up-stream levels of isoprenoids in the mevalonate
pathway leading to numerous cellular changes (Figure 1). For
example, intracellular accumulation of the substrate IPP leads
to accumulation of an ATP derivative, known as ApppI, which
inhibits themitochondrial adenine nucleotide translocase (ANT),
inducing cell apoptosis (Mönkkönen et al., 2006; Mitrofan et al.,
2009). IPP is also a natural antigen that directly stimulates γδ T
cells caring the Vγ2Vδ2 T cell receptors and is strongly impli-
cated in the human innate immune response against tumors
(Morita et al., 2007). Short hairpin RNA-mediated knockdown
of hFPPS in hematopoietic and non-hematopoietic tumor cell
lines has been shown to activate Vγ2Vδ2 T cells and induce
IFN-γ secretion (Figure 1) (Li et al., 2009; Wang et al., 2011).
Immunostimulation and increased Vγ9Vδ2 T cell-mediated cyto-
toxicity has been observed in animal models of human breast
cancer after treatment with N-BPs, suggesting an adjuvant role for
N-BPs in cancer chemotherapy (Benzaïd et al., 2012). Evidence
for the stimulation of Vγ2Vδ2-bearing T cells by N-BPs has also
been observed in MM patients treated with palmidronic acid
(4) (Kunzmann et al., 1999) and prostate cancer patients treated
with zoledronic acid (1a) (Naoe et al., 2010); in the latter case,
the observed T cell effects coincided with reduction in serum
prostate-specific antigen (PSA), providing further evidence of an
antitumor immune response in vivo (Naoe et al., 2010). It is note-
worthy that activation of γδ T cells in vitro has been reported
to correlate specifically with inhibition of hFPPS and has not
been observed with structurally related N-BPs that target other
downstream prenyl synthase enzymes, such as hGGPPS, hSQS
or decaprenyl pyrophosphate synthase (hDPPS) (Zhang et al.,
2010).
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ISOPRENOIDS FPPS/GGPPS AND
NEURODEGENERATION—THE CURRENT HYPOTHESIS
In the early 1990s, a series of reports from Sparks and co-
workers initiated a hypothesis linking the mevalonate pathway
to the Alzheimer’s disease (AD) (Sparks et al., 1990; Sparks,
1997). Evidence that dysregulation of the mevalonate pathway
is involved in the progression of neurodegeneration and that
high levels of plasma cholesterol may be among the main vascu-
lar risk factors of AD has been reported (Hoffman et al., 1997;
Marchant et al., 2013). Although not a universal finding (Wood
et al., 2014a), treatment of middle-aged individuals for hyperc-
holesterolemia with statins has been shown to confer some level
of neuroprotection against late-life development of AD (Jick et al.,
2000; Wolozin et al., 2007; Silva et al., 2013; Wood et al., 2014b).
Additionally, statin treatment has been shown to reduce the con-
centration of phosphorylated tau protein in the cerebrospinal
fluid of the human brain (Riekse et al., 2006). One of the early
pathological features of common AD is the progressive accumu-
lation of ribbon-like intraneuronal tangles made of polymer of
phosphorylated tau (P-Tau) protein, a key structural component
of the cytoskeleton of neurons. These findings are consistent with
the quasi-absence of cortical neurofibrillary tangles in autopsy-
confirmed cognitively intact subjects who had used statins for sev-
eral years as opposed to non-users (Li et al., 2007). Interestingly,
although statins can cause a significant reduction in phosphory-
lated tau levels in the cerebrospinal fluid of patients treated for
hypercholesterolemia, they do not seem to affect β-amyloid levels
(Riekse et al., 2006).
Higher concentrations of both FPP and GGPP in the brain
tissues of aged mice vs. younger mice have also been observed
(Hooff et al., 2012). Up-regulation of hFPPS and hGGPPS in the
brain of Alzheimer’s patients has been reported (Eckert et al.,
2009; Hooff et al., 2010). Furthermore, autopsy reports have indi-
cated that the levels of FPP/GGPP are significantly elevated in
gray and white matter of AD human brains, suggesting a disease-
specific role for hFPPS and hGGPPS. Isoprenoids can presum-
ably modulate Phospho-tau (P-Tau) levels in the human brain
via the metabolic cascade from FPP→GGPP→Cdc42→GSK3-β
(Figure 1) (Sayas et al., 1999; Ohm et al., 2003). The GSK3-β
kinase is (at least in part) responsible for high levels of tau phos-
phorylation (P-Tau) in neurons (Hooper et al., 2008). Current
research data indicate that decades prior to the onset of clinical
dementia, the accumulation of P-Tau protein seems to trigger the
formation of tangles, which progressively lead to neuronal cell
death. Therefore, the biochemical association between dysregu-
lation of isoprenoid biosynthesis and AD suggests that reducing
the P-Tau burden in the AD brain by inhibiting either hFPPS
or hGGPPS may decelerate (or stop) the progression of this dis-
ease. However, there is a considerable debate surrounding this
hypothesis and its validation requires the discovery of potent and
selective hFPPS and/or hGGPPS inhibitors with good biopharma-
ceutical properties that include significant permeability across the
blood-brain barrier.
HUMAN GGPPS
The geranylgeranylated GTPase proteins (e.g., Rho, Ram, Rac,
and Cdc42) play an indispensable role in signal transduction
cascades of cell growth, differentiation, and survival.
Although not identical, the pleiotropic biochemical con-
sequences of hGGPPS inhibition parallel those of hFPPS
inhibition. Consequently, numerous in vitro and ex vivo studies
have suggested hGGPPS as a therapeutic target. For example,
decrease in Rho kinase responses (as a consequence of statin
treatment) has been implicated in increased production of
endothelium-derived nitric oxide (NO) (Rikitake and Liao,
2005). Endothelial dysfunction is characterized as the decreased
synthesis, release, and/or activity of endothelial-derived NO and
is believed to be a strong predictor of cardiovascular diseases.
Therefore, the regulation of NO by Rho may be an important
mechanism underlying the cardiovascular protective effect of
statins. Geranylgeranylated GTPases are also implicated in onco-
genesis (Sorrentino et al., 2014). Inhibition of hGGPPS has been
reported to decrease the migration/metastasis of highly invasive
breast cancer cells (Dudakovic et al., 2011), induce autophagy in
prostate cancer (Wasko et al., 2011) and play a role in the survival
of glioma cells (Yu et al., 2014). Unfortunately, a clinically vali-
dated inhibitor of hGGPPS has not yet been identified, limiting
the validation of this enzyme as a therapeutic target.
HUMAN SQS
Squalene Synthase (SQS) is a microsomal enzyme catalyzing the
formation of squalene, the first committed step of the sterol
branch and cholesterol biosynthesis in the mevalonate pathway
(Figure 2). SQS can play a unique role in directing the flow of
the metabolite FPP to either the sterol or the non-sterol branch
of the pathway and due to this strategic location it is considered
an attractive target for antihyperlipidemic and antiatherosclerotic
therapies (Tansey and Shechter, 2001; Menys and Durrington,
2003; Do et al., 2009).
Despite the fact that today statins are the first line of treatment
against hypercholesterolemia (competitive HMG-CoA reductase
inhibitors), these drugs are often considered insufficient in pre-
venting cardiovascular diseases (Gilad and Lampl, 1999; Huynh
et al., 2002). Chronic inhibition of HMG-CoA reductase can
lead to decreased levels of numerous non-sterol metabolites
that are essential for cell viability (Levy and Kohlhaas, 2006).
Furthermore, recent clinical studies suggest that the use of high
doses of statins may lead to an increased risk of developing type II
diabetes. Although a potential mechanism for this phenomenon
is currently lacking, it has been suggested that statin-induced
myopathy may be associated with the development of muscle
insulin resistance (Mallinson et al., 2009). Nonetheless, given
the clinical benefits of statins in patients with moderate or high
cardiovascular risk factors, or existing cardiovascular diseases,
discontinuation of treatment with statins was not recommended
(Sattar et al., 2010; Preiss et al., 2011). The discovery of hSQS
inhibitors as potential antihyperlipidemic agents will provide an
alternative mechanism of action in treating hypercholesterolemia
and may allow the limitations of statins to be overcome.
INHIBITORS OF hFPPS
The clinically validated N-BP inhibitors of hFPPS, can be divided
into two structural sub-classes, the aromatic and aliphatic bispho-
sphonates. The former includes zoledronic acid (1a), risedronic
acid (2a), and minodronic acid (3), whereas the latter includes
pamidronic acid (4), alendronic acid (5), and ibandronic acid
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(6). Under physiological conditions, the side chain nitrogen of
N-BPs is presumed to be protonated and participate in bifurcated
hydrogen bond interactions with the side chain hydroxyl moiety
of Thr 201 and the carbonyl oxygen of Lys 200. These interactions
mimic those formed with the putative allylic carbocation inter-
mediate in the hFPPS catalytic cycle (Martin et al., 1999). These
interactions are also critical for the potency of N-BPs in inhibit-
ing hFPPS; for example, the phenyl analog of 2b is 280-fold less
potent than the pyridine derivative risedronic acid (2a) (Dunford
et al., 2008).
Previous efforts toward improving the clinical usefulness of N-
BPs focused on increasing the oral bioavailability, cell-membrane
permeability, and distribution to non-skeletal tissues. In prin-
ciple, all of these biopharmaceutical properties depend on
the physicochemical properties of the compounds. Pro-drug
approaches, such as masking the bisphosphonate pharmacophore
as a tetra ester (Zhang et al., 2006) or peptide pro-drugs (Ezra
et al., 2000), have been explored without advancing the clin-
ical use of these drugs. Formulation techniques using lipo-
some encapsulation of the parent N-BP compound have also
been explored as a means of improving oral bioavailability
and cell-membrane permeability (Shmeeda et al., 2010; Caraglia
et al., 2013). In addition, a number of structural modifications
aiming to reduce the acidity of the bisphosphonate pharma-
cophore, increase the overall lipophilicity of a compound and/or
decrease the affinity for bone, have been explored. Replacement
of the Cα-hydroxyl with a hydrogen (e.g., 2a vs. the corre-
sponding deoxybisphosphonate 2b) or Cα-halogen substituent
(e.g., 2c,d) has been found to decrease affinity for bone, as
well as the potency in inhibiting hFPPS (Marma et al., 2007).
Bisphosphonate inhibitors with various heterocyclic lipophilic
side chains, including derivatives of zoledronic acid (e.g., 1b,c)
pyridinium deoxybisphosphonates (7a–c) (Zhang et al., 2009),
aminopyridines (8a–d) (De Schutter et al., 2012; Lin et al., 2012),
azaindoles (Ebetino et al., 2010a,b) and imidazopyridines (9a–c,
respectively) (Ebetino et al., 2010c), and thienopyrimidines (e.g.,
10) (Leung et al., 2013a,b) have also been reported.
Although none of these analogs exhibit superior intrinsic
potency in inhibiting hFPPS, as compared to the best current
drugs (1a, 2a), they exhibit improved cell-membrane permeabil-
ity and lower bone affinity. For example, whereas the in vitro
potency of analogs 8c, 9b, and 9c is equivalent to that of the
drug 2a (all IC50 values ranging from 10 to 30 nM), these com-
pounds exhibit lower affinity for bone. This observation is con-
sistent with the hypothesis that the Cα-hydroxyl moiety, which
is commonly referred to as the “bone hook” is absent in these
analogs. Interestingly, the thienopyrimidine analog 10 was found
to exhibit higher affinity for bone than 2a, in spite of the absence
of the Cα-hydroxyl (Leung et al., 2013b). Preliminary evidence of
improved cell-membrane permeability by these more lipophilic
analogs has been deduced mainly from cell-based assays mea-
suring antiproliferation in various cancer cell lines. For example,
analog 7c was found to be ∼100-fold more potent than 1a in
inhibiting the proliferation of breast cancer MCF-7 cells (Zhang
et al., 2009), whereas analog 8b was shown to be slightly more
potent than 1a in inhibiting the MM cell lines RPMI-8226 and
KMS 28PE, in spite of a difference of nearly 10-fold in intrinsic
potency (Lin et al., 2012). Inhibition of ERK phosphorylation,
a signaling protein down-stream from Ras, was also observed
with analog 8b in KMS 28PE cells, providing evidence that this
compound inhibits the intended biochemical pathway (Lin et al.,
2012). At the present time, it is difficult to predict whether N-
BPs with much higher lipophilicity and lower affinity for bone
can provide sufficiently higher systemic exposure in vivo to sig-
nificantly alter the clinical profile of such compounds in treating
non-skeletal diseases.
The structural diversity of N-BPs and their corresponding
biological effects have also enriched our understanding of the
molecular recognition requirements for potency and selectivity
in inhibiting hFPPS vs. other functionally related enzymes. For
example, the pyridinium analogs 7a and 7b are more selective
in inhibiting hFPPS than hGGPPS, whereas derivatives with a
longer alkyl substituent, such as 7c, inhibit hFPPS, hGGPPS, and
hDPPS with very similar potencies (reported IC50 values for 7c in
inhibiting hFPPS, hGGPPS, and hDPPS are 100, 280, and 585 nM,
respectively) (Zhang et al., 2010). Crystallographic evidence with
FPPS from T. brucei suggested that the first four carbons of the
alkyloxy side chain can occupy the allylic sub-pocket, whereas,
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the longer analogs (e.g., 7c) force the hydrocarbon chain to fold
back, in order to avoid a steric clash with the protein surface of the
allylic sub-pocket (Zhang et al., 2009). In contrast, the conforma-
tionally rigid analogs 8a,d, and 10 bind in the allylic sub-pocket
by forcing the expansion of the binding cavity toward the cap-
ping phenyl (F98/F99), while maintaining selectivity for hFPPS
vs. hGGPPS; detailed characterization of the protein/ligand inter-
actions are discussed in the following section.
ALLOSTERIC INHIBITORS OF hFPPS
Highly “druggable” enzymes (Cheng et al., 2007) are character-
ized by the presence of well-defined, rigid, hydrophobic pockets
to which small molecules, with good “drug-like” properties (as
defined by Lipinski’s rule of five; Lipinski et al., 2001), can bind
and block their catalytic activity. In contrast, the prenyl synthase
enzymes hFPPS and hGGPPS are characterized by active sites
with a high density of charged amino acid residues and significant
conformational plasticity; such enzymes present a challenge for
drug discovery and are often branded as “undruggable” (Verdine
and Walensky, 2007; Crews, 2010). In fact, if it had not been for
the serendipitous discovery (more than 40 years ago) that bispho-
sphonates have clinical value as inhibitors of bone loss, hFPPS
could have easily been classified into this category of “undrug-
gable” targets (Russell, 2011). However, increasing awareness of
the pleiotropic effects that hFPPS inhibitors may have in human
non-skeletal diseases, has stimulated efforts toward the identifi-
cation of non-bisphosphonate inhibitors for this target. To date,
non-bisphosphonate active site inhibitors of hFPPS have not been
identified, and given the highly charged nature of the active site
cavity, the design of such compounds is unlikely. Consequently,
the focus has turned toward the identification of more “drug-
gable” allosteric pockets of this enzyme.
Fragment-based screening by NMR and X-ray crystallogra-
phy by Jahnke and co-workers at Novartis, led to the first dis-
covery of compounds (e.g., 11, 12) that bind in an allosteric
pocket of hFPPS near the IPP sub-pocket (Jahnke et al.,
2010). Subsequent optimization of these hits provided non-
bisphosphonate allosteric inhibitors with nanomolar potency
(e.g., 13, 14). At the same time, Novartis reported quinolone
(Amstutz et al., 2009) and salicylic acid (Cotesta et al., 2010)
derivatives (e.g., inhibitor 15 and 16, respectively) as inhibitors
of hFPPS. Although the binding interactions of these compounds
with the enzyme have not been disclosed, given their chemical
structure, it is highly unlikely that they bind to the active site of
hFPPS. Following these initial reports, in silico screening identi-
fied bisamidine-type inhibitors of hFPPS (e.g., 17) (Lindert et al.,
2013), although the binding mode of these compounds has also
not been reported. In our own efforts, multistage biochemical
and structural screening led to the discovery of thienopyrimidine
analogs (e.g., 18) that bind to the same allosteric pocket as com-
pound 13 and exhibit equivalent in vitro potency (De Schutter
et al., 2014).
In this account of examples from various structural classes
of hFPPS inhibitors, we have purposely avoided making system-
atic comparisons of the in vitro potencies of compounds pub-
lished by different research groups. Several different assays have
been reported in the literature for evaluating hFPPS inhibition
in vitro. The most commonly used method was originally devel-
oped by Reed and Rilling (1975) and has been adopted by many
researchers with only minor modifications (Marma et al., 2007;
Dunford et al., 2008; Lin et al., 2012); we refer to this assay as
method 1 (M1). As expected, the IC50 value of any compound
can vary considerably, depending on the assay method used for
screening. For example, the reported IC50 values of zoledronic
acid (1a) range from∼2–4 nM (Kavanagh et al., 2006a; Glickman
and Schmid, 2007; Dunford et al., 2008) to 200 nM (Amstutz
et al., 2009) and can be as high as 475 nM if the compound is
tested without pre-incubation with the enzyme (Dunford et al.,
2008). Experimental artifacts in a functional assay can further
contribute to the observed potency of a compound and mislead
SAR studies. Lipophilicity-dependent aggregation of moderately
(or poorly) hydrophilic compounds is the most common fac-
tor responsible for false experimental data and can affect both
in vitro and cell-based assays (Owen et al., 2012). The abil-
ity of bisphosphonates to form stable, high-order complexes in
solution, particularly in the presence of metal ions, is a well-
documented phenomenon, exploited in a number of biomedical
applications (Kunnas-Hiltunen et al., 2009; Freire et al., 2010;
Giger et al., 2013). Large lipophilic compounds, and particu-
larly the non-bisphosphonate inhibitors, are more likely to suffer
from solvent-induced hydrophobic interaction than the small
polar N-BP drugs. A number of assay modifications have been
reported that include lowering the concentration of Mg2+ ions
and adding Triton X-100 in the assay buffer (Peukert et al.,
2008; Lindert et al., 2013). Comparison of the intrinsic poten-
cies of all the known hFPPS inhibitors is very challenging, even
when compounds are tested under the same assay conditions.
For example, biological profiling of a series of bisphosphonate
and non-bisphosphonate inhibitors in the original M1 assay and
a modified assay that we developed (method 2; M2) revealed
minimal differences (<2-fold) in the IC50 values observed for
the small bisphosphonates, such as 2a and 8c, but significant
shifts of up to 20-fold with the lipophilic thienopyrimidine
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analogs (e.g., 10) and the allosteric inhibitors 13 and 14
(Leung et al., 2013b).
INHIBITORS OF hGGPPS
Compared with the well-studied hFPPS, there is little informa-
tion available on the structure of hGGPPS, and only a handful of
selective inhibitors for this target have been reported. All of the
known exploratory hGGPS inhibitors are bisphosphonates; how-
ever, none of the current bisphosphonate drugs targeting hFPPS,
such as 1a and 2a, exhibit any significant potency in inhibiting
hGGPPS. Bisphosphonates with long side chains, such as analogs
7c, 19, and 20, have been shown to inhibit hGGPPS (Szabo
et al., 2002; Zhang et al., 2009, 2010). Branched bisphosphonates,
such as the digeranyl analog 21 (Shull et al., 2006; Barney et al.,
2010) and the substituted biphenyl bisphosphonate 22, have been
described as selective hGGPPS inhibitors (Guo et al., 2007). The
X-ray structure of the S. cerevisiae GGPPS/22 complex showed
that this inhibitor occupies the equivalent site as seen in the
GGPP-bound hGGPPS structure (for a detailed discussion refer
to the section below).
Given the substrate/product selectivity of hGGPPS (C15/C20 iso-
prenoids, respectively) it is not surprising that bisphosphonates
with large side chains inhibit this enzyme. The reported potency
of these compounds (IC50 values) is in the range of 0.3–3μM
and none of the currently known hGGPPS inhibitors have been
advanced to clinical development.
INHIBITORS OF hSQS
Over the last two decades, various structural classes of squa-
lene synthase inhibitors have been described. These include
FPP substrate mimics, such as the bisphosphonate 23a, its
corresponding foscarnet derivative 23b (Biller et al., 1991),
the α-phosphonosulfonic acid 24 (Magnin et al., 1995, 1996;
Lawrence et al., 1996), and aromatic bioisosteres, such as com-
pounds 25–27 (Biller et al., 1993; Ciosek et al., 1993), Some of
these analogs were shown to inhibit hSQS with low nanomolar
IC50 potency. Furthermore, after intravenous and/or oral admin-
istration, some analogs lowered blood levels of cholesterol in
rat and hamster, without affecting the levels of dolichol and
coenzyme Q9 (Ciosek et al., 1993).
The second class of hSQS inhibitors includes mainly
transition-state analogs that mimic the electrostatic and topo-
logical properties of the putative carbocation intermediates
during the first and second steps in the catalytic conversion
of FPP to squalene (Figure 2). The main structural require-
ments in the design of these compounds include the incor-
poration of a large lipophilic moiety stimulating the binding
of the bulky and hydrophobic FPP hydrocarbon chain. In
addition, the presence of a basic nitrogen, which is protonated at
physiological pH, mimics the positive charge of the putative car-
bocation intermediate formed during the catalytic cycle; examples
include the pyridine analog 28 (Prashad et al., 1993). Cyclopropyl
amines, mimicking the structure of presqualene (Figure 2), have
also been described (Poulter et al., 1989). Interestingly, the
non-pyrophosphate derivative 29, failed to inhibit yeast SQS
in the absence of inorganic pyrophosphate (PPi), whereas in
the presence of PPi it exhibited potent synergistic inhibition of
the enzyme (Poulter et al., 1989). In contrast, the pyrophos-
phate derivative 30 was a potent inhibitor of SQS even in a
pyrophosphate-free buffer, suggesting the absolute requirement
of an ion pair during the rearrangement of presqualene pyrophos-
phate to squalene (Poulter et al., 1989).
Numerous molecules that are simpler to synthesize and more
drug-like, including the benzoxazole-based amines 31 and 32
(Ullrich et al., 1994; Morris et al., 1995), quinuclidine biphenyl
or quinolone (e.g., 33 and 34, respectively), and various other
amine-based SQS inhibitors (e.g., 35, 36) have been explored.
These molecules are also considered to act as mimics of the
postulated cyclopropyl cation intermediate in the rearrange-
ment reaction to squalene, a property that is attributed to their
substituted amine being protonated under physiological condi-
tions. However, the binding mode of these compounds remains
unknown. Many of these analogs were reported to exhibit SQS
inhibition activity in the low nanomolar or picomolar range
(Brown et al., 1995). The requirement for the presence of PPi in
the assay buffer (described above for analog 29) was also observed
with these inhibitors, making their in vivo potency somewhat
unpredictable. Nonetheless structural optimization led to the
identification of compounds with good biopharmaceutical prop-
erties, including reasonable oral bioavailability (Ishihara et al.,
2004). Quinuclidine derivatives in particular, such as 33 and 34
(Brown et al., 1996), exhibited an equal or better pharmacolog-
ical profile to statins in lowering cholesterol levels in hamsters,
guinea pigs and Rhesus monkeys (Amin et al., 1997; Brown et al.,
1997). However, none of these compounds were advanced to
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clinical trials; it is noteworthy that the quinuclidine structural
motif is believed to be responsible for the toxicities associated
with antimalarial drugs, such as quinine.
Natural products are a rich source of therapeutic agents and lead
structures for drug discovery. Zaragozic acids A (37), B, and C
are a family of fungal metabolites that have been shown to inhibit
hSQS (Baxter et al., 1992; Bergstrom et al., 1993). However, and in
spite of extensive SAR studies (Chan et al., 1996), the overall poor
biopharmaceutical properties of these compounds prevented
their development (Vaidya et al., 1998). Similarly, dicarboxylic
acid amphiphilic molecules, bearing structural resemblance to
zaragozic acids, have been explored. Examples include analogs
38 and 39, which are potent inhibitors of hSQS in vitro, and
can induce lowering of plasma cholesterol after oral adminis-
tration in animal models (Iwasawa et al., 1995; Fung et al.,
1997); further development of these compounds has not been
reported.
It has been proposed that statins are remarkably effective in
preventing cardiovascular events due to their combined choles-
terol lowering and antioxidant activity (Franzoni et al., 2003).
Inhibitors of the hSQS that are also endowed with antioxi-
dant and/or anti-inflammatory properties have been reported
to exhibit significant antihyperlipidemic and antiatherosclerotic
activity in vivo (Tavridou et al., 2007). The first generation of
such compounds is represented by the morpholine derivative
40 (EP2302) that combines antioxidant properties and hSQS
inhibition activity in vitro. It was reported that intraperitoneal
administration of 40 leads to significant decrease in total choles-
terol, low density lipoprotein, and triglycerides in the plasma of
Triton WR-1339 induced hyperlipidemic rats (Chrysselis et al.,
2000; Tavridou et al., 2008). Additional pharmacokinetic studies
of the modified derivative 41 revealed a 6 to 7-fold higher accu-
mulation of this compound in the liver (the main target tissue for
hSQS activity) vs. the blood (Matralis et al., 2011).
Recent studies suggest that loss of endothelium-derived NO
activity may contribute to the atherogenic process that includes
monocyte adhesion to the endothelial surface, platelet aggrega-
tion, vascular smooth muscle cell proliferation, and vasoconstric-
tion (Laufs et al., 1998). Morpholine derivatives that could inhibit
hSQS in addition to releasing nitric oxide, such as compound
42, were also explored (Chrysselis et al., 2002; Tavridou et al.,
2007). Furthermore, SAR studies of this series of compounds
include efforts to incorporate structural features of known antiox-
idant and/or anti-inflammatory, and even antidiabetic pharma-
cophores; examples include incorporation of the antioxidant
phenothiazine core (e.g., analog 44) and the side chain of the
non-steroidal anti-inflammatory agent naproxen (e.g., analog 43)
(Kourounakis et al., 2010; Ladopoulou et al., 2013; Matralis and
Kourounakis, 2014).
Finally, high throughput screening identified fused hetero-
cyclic compounds, typified by the benzoxazepine analog 45,
as inhibitors of the SQS enzymes from rat and hepatocellu-
lar carcinoma HepG2 cells (Miki et al., 2002a). SAR optimiza-
tion led to the discovery of analog 46a, with low nanomolar
potency in inhibiting both rat and HepG2 SQS (Miki et al.,
2002b). Pharmacokinetic investigations revealed that the primary
metabolite of 46a is the CYP-450 product 46b, which is rapidly
eliminated in the urine, but is also active in inhibiting SQS.
Structural modifications focusing on overcoming metabolic lia-
bilities without loss of potency were successful in identifying the
clinical candidate TAK-475 (47b). Although the binding mode
and molecular interactions of TAK-475 with hSQS have not been
reported, co-crystal structures of structurally related analogs have
been reported and will be discussed in a later section.
TAK-475 and its main metabolite, the deacetylated compound
47a, are both competitive inhibitors of hSQS with respect to
farnesyl pyrophosphate and exhibit good tissue distribution to
the liver (Miki et al., 2002c). TAK-475 was found to enhance the
binding of 125I-LDL to the LDL receptor and increase LDL recep-
tor expression in a manner similar to that observed with statins.
A decrease in total cholesterol and triglyceride plasma levels was
also observed in marmosets when TAK-475 was administered
at doses of 30 and 100mg/Kg without affecting HDL levels
(Nishimoto et al., 2003a). TAK-475 also delayed the progression
of coronary atherosclerosis in a rabbit model; interestingly,
changes of macrophage/lipid rich atheromatic plaques (that are
prone to rupture) into stable fibromuscular lesions were observed
and attributed to the lowering of oxidized lipoprotein content in
Frontiers in Chemistry | Chemical Biology July 2014 | Volume 2 | Article 50 | 8
Park et al. Human isoprenoid synthases as therapeutic targets
the plaques and an increase in CoQ10 levels (Shiomi et al., 2008).
In vitro testing in human rhabdomyosarcoma cells and human
skeletal muscle cells suggested that TAK-475 did not induce
myotoxicity [the most common side effect of statins, associated
with depletion of mevalonate derived isoprenoids (Nishimoto
et al., 2003b)], and surprisingly when co-administered with
statins to guinea pigs, TAK-475 seemed to decrease statin-induced
myotoxicity (Nishimoto et al., 2007). In spite of all the favorable
properties of TAK-475 (47b), lack of superiority in clinical ben-
efits as compared to current standard of care (i.e., treatment with
statins), in addition to liver toxicity at the dose required to achieve
efficacy, led to termination of its clinical development (Stein
et al., 2011). Nonetheless, SQS is still considered a viable target
for drug discovery in the treatment of atherosclerosis (Liao, 2011)
and new derivatives of TAK-475, such as the tricyclic pyrrole
derivative 49, are still under investigation (Ichikawa et al., 2013).
STRUCTURES OF PRENYL SYNTHASE
ENZYMES—IMPLICATIONS FOR DRUG DISCOVERY
Structure-based rational drug design provides a creative, efficient
alternative to high-throughput screening approaches commonly
used in industry for the identification of hit or lead compounds
(Lounnas et al., 2013). Since this approach relies on detail knowl-
edge of the molecular recognition elements between ligands and
targets, three dimensional atomic structures of potential thera-
peutic targets, particularly in complex with ligands/inhibitors, are
highly valuable. Owing to on-going technological advancements
in the methods used in macromolecular structure determina-
tion, increasing numbers of pharmaceutical targets are becom-
ing amenable to structure-based approaches (Thiel, 2004). The
prenyl synthase enzymes, particularly hFPPS, undergo signifi-
cant conformational changes during catalysis and are involved
in “induced fit” binding interactions with their inhibitors; typ-
ically, such properties make structure-based drug design more
challenging. Nonetheless, detail knowledge of the molecular
interactions between inhibitors of these enzymes and their bind-
ing pockets is indispensable in guiding medicinal chemistry
efforts.
HUMAN FPPS
Numerous co-crystal structures of hFPPS are currently avail-
able, in complex with various ligands, including the best current
N-BP clinical drugs. These structures have provided tremen-
dous insights into the catalytic cycle, protein-ligand binding
interactions, and future drug design strategies for this target.
Here, we aim to summarize the great wealth of structural infor-
mation presently available on hFPPS in complex with various
inhibitors.
OVERALL STRUCTURE
The structure of hFPPS was first determined in 2006, simul-
taneously by two independent groups (Kavanagh et al., 2006a;
Rondeau et al., 2006). The enzyme exists as a homodimer of a
41 kDa subunit and has an all α-helical structure, a feature also
shared by hGGPPS and hSQS (Figure 3). The hFPPS monomer is
comprised of ten core helices (αA-αJ), constituting its main body
around a central catalytic cavity, and three short helices (α1-α3)
inserted between αH and αI that form a small peripheral domain
(Figure 3A). This domain, which is absent in prokaryotic FPPS
(Hosfield et al., 2004), may function as a binding interface for
interaction with other proteins. The two aspartate-rich (DDXXD)
motifs conserved across all species and also in GGPPS are located
at the end of αD and αH, and face the central cavity from oppo-
site sides (Figure 3A). These motifs are followed immediately
by extended loop regions (Ser108-Asp127 and Leu248-Ser268),
which shape a large portion of the outer perimeter of the active
site cavity. Overall, the ligand-free form of the hFPPS monomer
can be described as consisting of two similarly sized lobes sep-
arated by a large deep cleft containing the active site. Enzyme
dimerization is mediated by the N-terminal lobe, with the dimer
interface formed mainly by αE and αF.
ALLYLIC SUBSTRATE BINDING SITE
The DDXXD motifs in hFPPS are essential for the binding of
the allylic substrates DMAPP and GPP. The substrate ligation
occurs primarily through threeMg2+ ions andmetal-coordinated
water molecules that mediate the binding interactions between
the aspartate residues and the pyrophosphate of the isoprenoids.
The conserved residues Arg112, Lys200, and Lys257 also con-
tribute to the substrate binding by forming direct salt bridges with
the pyrophosphate. The bisphosphonate inhibitors of hFPPS act
competitively with respect to the allylic substrates and bind to the
enzyme in an analogous manner, with their bisphosphonate moi-
ety mimicking the pyrophosphate of the substrates (Figure 4A).
Substrate/inhibitor binding brings the DDXXD motifs closer
together, resulting in a major conformational change involving
a rigid body motion of the entire C-terminal lobe. The structural
transition drastically reduces the volume of the centrally located
cavity and shuts its opening to the allylic substrate binding site,
forming a discrete pocket around the trinuclear Mg2+ cluster. It
is currently unknown whether Mg2+ ions and the ligands (i.e.,
the allylic substrates or bisphosphonate inhibitors) bind to hFPPS
sequentially or as a preformed cluster.
In addition to the 3Mg2+/pyrophosphate (or bisphosphonate)
binding area, the allylic substrate sub-pocket consists of a deep
hydrophobic channel that accommodates the isoprenyl hydro-
carbon tail of the substrate or the side chain of a bisphospho-
nate inhibitor (Figure 4B). The channel extends to the enzyme’s
dimerization interface, where the residues Ile143, Asn144, and
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FIGURE 3 | Overall structures of human prenyl synthase enzymes.
(A) Farnesyl pyrophosphate synthase (PDB ID: 2F7M); (B) geranylgeranyl
pyrophosphate synthase (PDB ID: 2Q80), and (C) squalene synthase
(PDB ID: 3WEG). The enzymes are shown in a blue-to-red rainbow color
scheme. For hFPPS and hGGPPS, one monomeric subunit of the enzyme
oligomer is represented in color. The conserved aspartic-acid rich motifs
are shown in a stick representation and marked by arrows. The small
domains composed of α1-α3 in hFPPS and hGGPPS are indicated by
elliptical circles; in this view, the α1 in hFPPS is hidden behind the top
portion of αH.
Asn147 of the adjacent monomer form a dead-end wall. Asp103,
the first aspartate residue of the N-terminal DDXXD motif, is
found at the opening of this channel and likely functions as
its gatekeeper. Without the Mg2+ ions bound to the conserved
motif the side chain of Asp103 points into the opening, rendering
it too narrow to accommodate an isoprenyl chain or a struc-
turally similar mimic (e.g., PDB IDs: 2F7M and 2RAH). Other
residues of importance for forming this channel include Phe98,
Phe99, and Gln171 (Figure 4B). Besides providing a hydropho-
bic surface for the tail of the allylic substrate, the phenylala-
nine residues play a key role in determining the length of the
final product’s hydrocarbon chain (i.e., C15 for FPP) (Tarshis
et al., 1996). Gln171 also facilitates binding of the allylic tail
via π-stacking interaction involving its planar side chain, but
this residue further contributes to substrate binding by provid-
ing a polar contact to the pyrophosphate-Mg2+-water cluster.
In our work, we have shown that these residues participate in
similar interactions with bisphosphonate inhibitors that have
extended and rigid lipophilic side chains, such as the aminopyri-
dine inhibitors 8a and 8b (Figure 4B) (De Schutter et al., 2012;
Lin et al., 2012), and the thienopyrimidine-based inhibitor 10
(Leung et al., 2013b).
The hFPPS catalysis is thought to proceed as a three-
step ionization-condensation-elimination reaction in which the
nucleophilic tail double bond of IPP attacks the C1 atom of
the allylic substrate (i.e., DMAPP or GPP) (Cornforth et al.,
1966; Poulter et al., 1978). The initial ionization of the allylic
substrate is triggered by the bound Mg2+ ions and generates a
pyrophosphate as well as an allylic carbocation with its charge
distributed over the C1, C2, and C3 atoms. The carbocation
intermediate is stabilized through electrostatic interactions with
the liberated pyrophosphate and polar interactions with the main
chain carbonyl oxygen of Lys200 and the side chain oxygens of
Thr201 and Gln240 (Hosfield et al., 2004). As discussed ear-
lier, the oxygen atoms of Lys200 and Thr201 form a bifurcated
H-bond with the protonated heterocyclic nitrogen of the most
potent current N-BP drugs, minodronate (3, PDB IDs: 2VF6;
3B7L), zoledronate (1a; Figure 4A; PDB IDs: 1ZW5, 2F8C, 2F8Z,
2F9K), and risedronate (2a, PDB ID: 1YQ7; 1YV5), which is pre-
sumed to be protonated in the enzyme bound state. N-BPs with
alkyl amine side chains, such as pamidronate (4, PDB ID: 2F89)
and alendronate (5, PDB ID: 2F92), are significantly less potent
(>50-fold loss in potency as compared to 1a, 2a, or 3). In the
past, this loss in potency was attributed (at least in part) to the
preference for having a nitrogen atom four bonds away from the
Cα for best alignment and H-bond distance from the oxygens of
Lys200 and Thr201 in the bound state. However, the potency of
these compounds is affected by multiple factors, including the
basicity of the nitrogen-containing side chains and the energy
required for desolvation of the side chain before binding to the
enzyme; the latter effect may account in part of the potency
difference between the primary amine analog pamidronate (4)
and the much more lipophilic tertiary amine derivative iban-
dronate (6; the nitrogen atom is three σ-bonds away from the
Cα in this compound). Additional interactions of the longer side
chain of 6 with the lipophilic region consisting of the capping
phenyls, is accompanied with minor conformational changes to
the allylic sub-pocket (PDB ID: 2F94); ibandronate is only ∼5-
fold less potent than the most potent N-BP drugs (Dunford et al.,
2008).
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FIGURE 4 | Structure of human farnesyl pyrophosphate synthase.
(A) Binding of zoledronate (1a) at the allylic site (PDB ID: 2ZW5).
Mg2+ ions and water oxygen atoms are shown as yellow and red
spheres, respectively. Yellow dashes indicate molecular interactions.
(B) Binding of compound 8a (PDB ID: 4DEM). The hydrophobic channel
accommodating the side chain of the inhibitor is rendered in a
semi-transparent surface representation. (C) Binding of IPP at the
homoallylic site (PDB ID: 4H5E). (D) Conformational changes responsible
for structuring the C-terminal tail. (E) Binding of compound 13 at the
allosteric site (PDB ID: 3N6K).
IPP BINDING SUB-POCKET (HOMOALLYLIC SUBSTRATE BINDING SITE)
The IPP binding sub-pocket is only fully shaped upon occupancy
of the allylic sub-pocket which results in the previously described
conformational change that partially closes the active site cavity.
This sub-pocket is composed mainly of basic residues, includ-
ing the highly conserved residues, Lys57, Arg60, and Arg113,
which form direct salt bridges with the pyrophosphate of the
bound IPP. Three other residues, Arg112, Lys257, and Arg351,
participate in indirect interactions through water molecules
(Figure 4C). Additional interactions to the IPP pyrophosphate at
this site include a direct H-bond with Gln96 and water-mediated
H-bonds with Asn59 and Glu93 (Figure 4C). Conserved residues
Leu100 and Phe239, on the other hand, provide hydrophobic con-
tacts to the homoallylic tail of IPP (Figure 4C). These interactions
position the tail double bond of IPP close to the C1 atom of the
allylic substrate, thus facilitating the nucleophilic attack during
catalysis. The IPP tail likewise makes tight van der Waals contacts
with the side chain of a bisphosphonate inhibitor. This interac-
tion further stabilizes the bound inhibitor thus contributing to
potency.
hFPPS C-TERMINAL TAIL
The initial occupancy of the allylic sub-pocket induces a protein
conformational change from the “open” to a “partially-closed”
state, which fully defines the shape of the IPP binding site.
The subsequent binding of IPP leads to folding and rigid-
ification of C-terminal tail residues (350KRRK353) over the
IPP binding site (Figure 4D), completely closing the active
site cavity and sequestering both substrates from bulk water
(Song and Poulter, 1994). While hFPPS cycles through its
three conformational states during catalysis, with chemically
stable bisphosphonate inhibitors the ternary enzyme complex
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stalls in the fully closed state. This nearly irreversible inhi-
bition of the enzyme is partly responsible for the clinical
efficacy of the bisphosphonate compounds (Räikkönen et al.,
2011).
The C-terminal tail closure of hFPPS is most notably charac-
terized by rigidification of the Arg351 side chain, which anchors
itself to the αH, in addition to forming a salt bridge with the
terminal residue Lys353 (Figure 4D). The anchoring of Arg351
requires a cascade of preceding conformational changes in the
residues Gln242, Phe238, and Tyr349. Tyr349 here likely func-
tions as a safety switch preventing futile tail closure in the
absence of bound IPP. When the side chain of Tyr349 is locked
in the “off” position, the downstream conformational changes
are inhibited by steric hindrance (Figure 4D). The IPP-induced
tail closure is intriguing because the ligand when bound does
not make any direct contact with either the tail residues or the
switch residue Tyr349. A putative mechanism as to how the sub-
tle conformational change triggered by IPP binding at the IPP
sub-pocket translates into such a drastic movement of Tyr349
(i.e., the side chain rotation of ∼80◦, Figure 4D) has been pro-
posed recently (Park et al., 2012): the pyrophosphate of IPP
attracts and structures the side chain of Lys57, while pushing
back Arg60; the displacements of these residues result in a ∼15◦
rotation of Asn59, which in turn interacts with Lys347 through
a recruited water molecule (Figure 4D). The ordered side chain
of Lys57, on the other hand, attracts the enzyme’s C-terminal
tail by forming a salt bridge with the terminal carboxyl group
(Figure 4D). The force applied simultaneously to the residues
upstream and downstream of Tyr349 by these interactions may
create a torque strong enough to rotate its side chain out of its
“off” conformation.
Interestingly, inorganic pyrophosphate (PPi) can also bind to
the homoallylic site of hFPPS and elicit the tail-closing con-
formational change in the presence of a bound bisphosphonate
(Park et al., 2012). An implication of this observation is that
PPi, which is a prevalent cellular metabolite, may have a rel-
evant role in stabilizing an enzyme-inhibitor complex in vivo.
On the contrary, inorganic phosphate (Pi) can bind to the IPP
binding site (up to two molecules simultaneously), but does not
appear to induce this conformational change (Park et al., 2012,
2014). Other anions observed to bind to the IPP sub-pocket of
hFPPS include sulfate (PDB IDs: 2RAH; 3RYE; 3S4J; 4JVJ); sim-
ilarly, bound acetate has been observed with FPPS from T. brucei
(PDB IDs: 2OGD, 3DYG; Zhang et al., 2009). It is currently
unknown whether the binding of Pi or other negatively charged
cellular metabolites is physiologically relevant. However, it is con-
ceivable that any non-substrate compound binding at the IPP
sub-pocket would also inhibit the enzyme by competing with
IPP. Indeed, in vitro inhibition of porcine FPPS by Pi (albeit at
a high concentration) has been reported (Holloway and Popjak,
1967). In this light, it is noteworthy that cross-binding of iso-
prenoid substrates, such as binding of IPP to the allylic site of
hFPPS (Kavanagh et al., 2006a) and of DMAPP to the homoal-
lylic site of T. cruzi FPPS (Gabelli et al., 2006), have also been
reported. However, no bisphosphonate or other small molecular
compound that targets specifically the IPP binding site has been
identified.
ALLOSTERIC POCKET
Recently, non-bisphosphonate inhibitors of hFPPS have been
identified by a fragment-based, structure-guided approach
combining NMR spectroscopy and X-ray crystallography (Jahnke
et al., 2010). These inhibitors bind in a newly identified pocket
adjacent to the IPP sub-pocket and near the C-terminal end
of the enzyme (Figure 4E). This pocket is lined with αC, αG,
αH, and αJ, and is largely hydrophobic with contributions from
the entire side chains of Phe206, Pro209, Phe239, Lue344, and
Ile348, as well as the alkyl portions of the Asn59, Arg60, and
Lys347 side chains. The initial fragment hits and the opti-
mized compounds all contain a bicyclic or tricyclic heteroaro-
matic system with at least one carboxylic acid group. Most of
these compounds bind through hydrophobic and/or π-stacking
interactions between their heteroaromatic groups and the pro-
tein residues within this pocket. In addition, one of the car-
boxylic acid moieties of these compounds forms electrostatic
interactions with the side chains of Arg60 and Lys57, as well
as an H-bond with the side chain of Asn59 (Figure 4E). The
mechanism of action of the allosteric inhibitors is thought
to involve blocking the C-terminal tail from closing, inhibi-
tion of IPP binding due to electrostatic repulsion (between
the carboxylic acid moiety and the pyrophosphate moiety) and
disruption of the overall dynamics of the enzyme’s catalysis
cycle.
The discovery of the hFPPS allosteric pocket was unforeseen,
since in the absence of a bound ligand, the pocket is small and
only widens upon ligand binding via an induced-fit mechanism.
It is presently unknown whether this pocket has a natural phys-
iological role and whether it is truly highly druggable; proof of
the latter will have to await the identification of very potent
inhibitors of hFPPS that bind to this pocket and inhibit hFPPS
in vivo.
HUMAN GGPPS—OVERALL STRUCTURE
In contrast to hFPPS (presently, 36 released and 20 unre-
leased PDB entries), there has been only one structure of
hGGPPS reported so far (Kavanagh et al., 2006b). Like its par-
alog hFPPS, hGGPPS adopts an all α-helical fold (Figure 3B),
and the monomer associates into a homodimer. However, three
dimers of this enzyme join together to form a homohexamer
complex, which has been described as a three-blade propeller
(Figure 3B). Biochemical investigations have even described the
formation of octameric complexes in solution (Miyagi et al.,
2007). Despite low sequence identity (17%), the tertiary structure
of hGGPPS is remarkably similar to that of hFPPS (Figure 3A).
The two aspartate-rich (64DDIED68 and 188DDYAN192) motifs
are found at locations equivalent to those in hFPPS, also facing
the central catalytic cavity from opposite sides (Figure 3B); how-
ever, the C-terminal motif is replaced by DDXXN. Additionally,
hGGPPS is a smaller protein than hFPPS, it has an extended
loop region following this C-terminal motif that contains a
short α-helical element (Figure 3B) and lacks the N-terminal
helix αA found in hFPPS (Figure 3B). Other secondary struc-
ture elements of hGGPPS are analogous to those described
for hFPPS earlier, namely αB-αJ and α1-α3. Notably, the small
domain composed of α1-α3 in hGGPPS is involved in forming
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the inter-dimer contacts with αB and the first extended loop
region of the adjacent subunit (Figure 3B). The dimerization
interface is formed mainly by αE and αF from each monomer
in a two-fold symmetry-related fashion as also observed in
hFPPS.
INTER-DIMER INTERFACE
The core of the inter-dimer interface is composed of a hydropho-
bic patch formed by the small domain residues Ile233, Ile243,
and Tyr246, and the N-terminal residues Tyr18, Phe76, Pro77,
Ile82, and Tyr83 of the contacting subunit (Figure 5A). This con-
tact is further stabilized by the H-bond interactions between
Thr228 and Glu14, Gln236 and Ile82, and Tyr246 and Gln21
(Figure 5A). There are six such contacts in the entire hex-
amer, with each monomer contributing both the small domain
and the N-terminal interactions. The residues involved in the
inter-dimer contacts are conserved in mammalian andDrosophila
GGPPS but not in plant, fungal, archaeal, or bacterial orthologs
(Kavanagh et al., 2006a). This observation suggests that the hex-
americ organization of GGPPS quaternary structure is likely
characteristic only of the mammalian and insect enzymes. All
the other orthologs whose structures have been determined,
including fungal and bacterial forms, display a dimeric orga-
nization. The relative abundance of structural information
available on GGPPS from other organisms (>40 PDB entries
released), as well as the low resolution (2.70 Å) of the reported
human structure, suggests that the human enzyme is diffi-
cult to crystallize perhaps due to its hexameric nature. A large
part of the discussion below therefore relies on known struc-
tures of other GGPPS orthologs, particularly those of the yeast
enzyme (Guo et al., 2007; Zhang et al., 2009), as well as
hFPPS.
FIGURE 5 | Structure of geranylgeranyl pyrophosphate synthase.
(A) The inter-dimer interface in hGGPPS (PDB ID: 2Q80). (B) Binding
of a bisphosphonate with a long alkyl side chain to yeast GGPPS
(PDB ID: 2Z4X); the trinuclear metal cluster is similar to that in
Figure 4A. (C) The product chain elongation channel in hGGPPS.
(D) Binding of the substrate FPP in yeast GGPPS (PDB ID: 2E90);
conformational changes of the key residues (as compared to the
same residues in C) are evident; also Ala59 in hGGPPS is replaced
with a serine in yeast GGPPS. (E) Binding of GGPP at the product
inhibitory site in hGGPPS.
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CATALYTIC CAVITY
Both the allylic (FPP) and homoallylic (IPP) substrate binding
sites of hGGPPS are highly comparable to those previously dis-
cussed for hFPPS. The allylic substrate site is capped by the
DDXX(D/N) motifs and the proceeding loop regions. FPP bind-
ing is thought to occur in a similar arrangement as observed
for the binding of DMAPP/GPP in hFPPS, where three Mg2+
ions mediate the interaction between the side chains of the acidic
residues and the pyrophosphate moiety. The basic residues that
form direct contacts with the GPP/DMAPP substrate in hFPPS
are also conserved for the binding of FPP in hGGPPS (i.e.,
Arg73, Lys151, and Lys202). The exact details of the metal medi-
ated charge interaction, however, are unclear from the available
structural model (PDB ID: 2Q80); in this case, only two Mg2+
ions are observed bound to the N-terminal DDXXD motif, and
there are no water molecules coordinated with them. In addi-
tion, the Mg2+ ion interacting with the second DDXXD motif
observed in hFPPS is missing entirely in this hGGPPS structure.
While these discrepancies are probably due to the resolution lim-
itation of the current hGGPPS structure, the higher resolution
structures of the yeast enzyme also show varying numbers of
chelated Mg2+ ions (i.e., 0–3), as well as diverse water coordi-
nation patterns. The reason for these inconsistencies may also lie
in the fact that all of the substrate and inhibitor ligands bound
to the yeast enzyme were introduced by soaking rather than
co-crystallization. Alternatively, buffer pH effects resulting in pro-
tonation of the conserved aspartic acid residues and thus affecting
the metal binding have also been suggested (Guo et al., 2007).
Nonetheless, two structures of yeast GGPPS (PDB IDs: 2Z4X
and 2Z52) show three Mg2+ ions and octahedrally coordinated
water molecules mediating bisphosphonate binding in a manner
analogous to that observed for hFPPS (Figure 5B).
The location and nature of the hydrophobic channel accom-
modating the allylic substrate’s isoprenyl C15 tail in hGGPPS are
also similar to those for hFPPS. However, in hGGPPS Ala59 and
Ser60 replace the capping phenyls of Phe98/99 in hFPPS (that
limit the growing chain length to C-15), thus allowing space
for the C20 isoprenoid product of this enzyme (Figure 5C vs.
Figure 4B). In addition, three nearby leucine residues (Leu56,
Leu122, and Leu155), undergo rotational changes upon substrate
binding and form the deepest corner of this hydrophobic chan-
nel to accommodate the end portion of the substrate’s aliphatic
tail (by analogy with yeast GGPPS; compare Figure 5C and
Figure 5D).
The IPP substrate binding site in hGGPPS (like in hFPPS) is
lined with basic residues that interact directly with the pyrophos-
phate of IPP (i.e., Arg28, His57, Arg73, and Arg74). Lue61 and
Phe184 provide hydrophobic contacts to the IPP hydrocarbon tail
and direct it toward the C-1 of the allyllic substrate. By analogy
with hFPPS, hGGPPS catalysis is thought to proceed via the same
ionization-condensation-elimination mechanism described pre-
viously. In support of this hypothesis, the three residues proposed
to stabilize the allylic carbocation intermediate in hFPPS are all
conserved in hGGPPS (i.e., Lys151, Thr152, and Gln185).
INHIBITORY CONFORMATION/POCKET
It is notable that the only human GGPPS structure available
shows a molecule of GGPP in complex with each monomer.
Evidently, during heterologous bacterial expression of the
human recombinant GGPPS enzyme, bacterial GGPP bound
was retained though the enzyme purification and crystallization
process (Kavanagh et al., 2006b). In this structure, the GGPP
molecule does not represent the product state, as its pyrophos-
phatemoiety is bound to the DDXX(D/N)motifs in the allylic site
as opposed to the basic residues in the homoallylic site (IPP sub-
pocket). Furthermore, its hydrocarbon tail extends down into a
large, deep pocket below the active site (Figure 5E), and not into
the hydrophobic channel believed to accommodate the growing
isoprenyl tail of the product. This novel pocket has a hydropho-
bic surface, lined with the aliphatic and aromatic side chains of
the residues Arg28, Leu31, Phe35, His57, Leu155, Phe156, Ala159,
Val160, and Phe184. The enzyme-ligand complex here is thought
to demonstrate a feed-back inhibitory state; this observation
is consistent with GGPP and 3-azaGGPP acting as competitive
inhibitor of hGGPPS with respect to the substrate FPP (Kavanagh
et al., 2006a).
As a consequence of hGGPPS having two large hydropho-
bic sub-pockets in its active site cavity, the enzyme may allow
binding of larger lipophilic bisphosphonates (e.g., compounds 21
and 22) in multiple binding orientations. In the absence of co-
crystal structures of the human GGPPS with inhibitors, co-crystal
structures of the yeast GGPPS have shown diverse binding pat-
terns for various compounds (Guo et al., 2007; Cao et al., 2008;
Zhang et al., 2009). Some analogs bind in the allylic substrate site
(similarly to the binding of small N-BPs in hFPPS), with their
bisphosphonate moiety ligated to the DDXX(D/N) motifs and
their side chains extended into the tail elongation site (e.g., PDB
entries 2Z4X and 2Z52), whereas others bind like GGPP (in its
inhibitory conformation) with their lipophilic side chains occu-
pying the product inhibitor pocket (e.g., PDB entries 2Z7H and
2ZEV). In addition, compounds that bind simultaneously at two
separate sites have been identified. With these bisphosphonates,
one molecule binds at the allylic substrate site, and the other at
the IPP binding site but with its bulky side chain in the inhibitory
pocket (PDB IDs: 2E93 and 2Z4Y). Furthermore, bisphospho-
nate compounds that are branched at the Cα with long aliphatic
groups bind to the allylic substrate site with one side chain in
the tail elongation channel and the other in the inhibitory pocket
(e.g., PDB: 2Z4W and 2Z4Z). In summary, the current structural
information of GGPPS/ligand complexes suggest that there are
many challenges to overcome in targeting the human enzyme and
in understanding themolecular recognition elements required for
the design of selective and potent inhibitors.
HUMAN SQUALENE SYNTHASE (SQS)
OVERALL STRUCTURE
Human SQS (hSQS) is a 417 amino acid, 47-kDa enzyme local-
ized at the endoplasmic reticulum, where it is anchored to the
membrane with both of its terminal ends, while its larger cat-
alytic domain is facing the cytosol. The crystal structure of the
soluble, functional, doubly truncated form of hSQS (residues 31–
370) was first determined by Pandit et al. (2000), and since then
a number of additional structures with bound inhibitors have
become available (Ichikawa et al., 2011, 2012; Liu et al., 2012). The
protein is entirely α-helical (αA-αM), and despite the lack of over-
all sequence homology, its core helices surrounding the central
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catalytic cavity (αC, αF-αH) are structurally analogous to those
of hFPPS and hGGPPS (αD, αF-αH) (Figure 3C). The enzyme
contains two conserved signature (DXXED) motifs, which are
found on opposite walls of the catalytic cavity with the aspartate
and glutamate side chains pointing into the cavity (Figure 3C).
Of note, structural superposition shows that the DXXED motifs
of hSQS occupy the same spatial locations as the DDXX(D/N)
motifs of hFPPS and hGGPPS. The same chain fold and similar
active site topology, as well as the conservation of function-
ally important residues, strongly suggest a distant evolutionary
relationship between hSQS and hFPPS/hGGPPS.
CATALYTIC CAVITY
The hSQS catalysis proceeds in a two-step reaction where the
reductive “head to head” condensation of two FPPmolecules first
produces a stable cyclopropylcarbinyl diphosphate intermediate
(Figure 2), the presqualene pyrophosphate (PSPP), which then
undergoes heterolytic isomerization, and reduction byNADPH to
give squalene (Figure 2). Binding of the two substrate molecules
and the reaction intermediate are best characterized with the
recently released crystal structures by Liu and co-workers (PDB
IDs: 3WEG, 3WEH, 3WEI, 3WEJ, and 3WEK). The pyrophos-
phate of the donor FPP molecule, which yields the allylic car-
bocation for the first half reaction, binds in between the two
DXXED motifs with three Mg2+ ions mediating the interaction
in a pattern similar to those described for hFPPS and hGGPPS
earlier (Figure 6A). The pyrophosphate of the acceptor FPP, on
the other hand, binds near the flexible loop connecting αA and
αB (i.e., Ser51-Phe54), often referred to as the “flap,” via direct
interactions with residues of the loop as well as nearby residues,
Tyr73 and Arg77 (Figure 6A). The isoprenyl tails of the both
FPP molecules extend into a large, deep hydrophobic pocket
FIGURE 6 | Structure of human squalene synthase. (A,B) Binding of the
substrate mimic farnesyl thiopyrophosphate to hSQS (PDB ID: 3WEG). The
Arg52 side chain is omitted for clear view of the two pyrophosphate groups in
(A). The large hydrophobic cavity that accommodates the substrate tails is
represented in (B). (C) Binding of the reaction intermediate PSPP shown in
the same orientation as in (A) (PDB ID: 3WEH). For clarity of the view,
residues (redundant with those in A) are not labeled. (D) Binding of a
bisphosphonate inhibitor, compound 27 (PDB ID: 3LEE). (E) Binding of a
benzoxazepine inhibitor, compound 49 (PDB ID: 3V66). (F) Binding of
zaragozic acid A (38) (PDB ID: 3VJC).
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in the center of the protein (Figure 6B). The residues Ile58,
Val69, Phe72, Tyr73, Lue76, Arg77, Val175, and Lue183 provide
hydrophobic contacts for the donor FPP tail on one side, and
Ala176, Phe187, Met207, Leu211, and Tyr276, for the acceptor
FPP tail on the other side. The residues Phe54, Val179, Lue183,
and Phe288, lining the middle of the pocket, interact with the
both FPP tails. The tails also make tight van der Waals con-
tact with each other, which likely further stabilizes their binding
to the enzyme. After the first half reaction, the intermediate
formed (i.e., PSPP) stays bound at the same site although the
conformation of the αAαB flap changes slightly (Figure 6C vs.
Figure 6A).
To date, the binding of NADPH to hSQS has not been fully
characterized (crystallographically) and there is no sequence
found in this enzyme that is similar to the known pyridine
nucleotide binding motifs. However, the protein depression
formed by the residues Phe54, Lue211, Pro292, Met295, and
Ala296 has been proposed as the cofactor binding site based on
its location, as well as the conservation of these residues across
all species (Liu et al., 2012). In support of this notion, this cav-
ity is not conserved in related enzymes that do not require the
nucleotide cofactor, such as dehydrosqualene synthase. The adja-
cent flexible region composed of the αK and the following loop
may also be involved in the binding of NADPH and/or function
as a lid that regulates the access of the cofactor to its binding site.
INHIBITOR BINDING
Owing to the nature of its catalytic activity and the structures
of its substrate, intermediate and product (Figure 2), hSQS has
a very large active site cavity with various binding motifs for
multiple ligands. Consequently, a number of structurally diverse
classes of hSQS inhibitors have been reported. Some of the
inhibitors have been co-crystallized with the target enzyme, and
the crystal structures clearly demonstrate different bindingmodes
of these compounds. For example, compound 27 (BPH-652),
a representative of a substrate analog, binds to the donor FPP
binding site in the same manner as the natural substrate FPP
(PDB ID: 3LEE) (Figure 6D). The inhibitor’s phosphonosul-
fonate group binds to the DXXED motifs, and its diphenylether
side chain occupies one side of the substrate tail binding pocket,
making close hydrophobic contacts with the aromatic and alkyl
side chains of the residues Phe54, Ile58, Val69, Phe72, Tyr73,
Lue76, Val179, Leu183, and Phe288 (Figure 6D). In contrast,
benzoxazepine-based compounds, such as 47 and 48, bind to
hSQS through interactions with the substrate tail binding pocket
and with the αAαB flap (PDB IDs: 1EZF, 3ASX, 3Q2Z, and 3V66)
(Figure 6E). The benzoxazepine scaffold sits at the base of the
hydrophobic pocket, with the dimethoxyphenyl substituent occu-
pying the deepest corner of this pocket, formed by the residues
Leu183, Ser184, Phe187, Ala204, Met207, Phe288, and Cys289
(Figure 6E). These inhibitors also have a structurally varied sub-
stituent containing a (di)carboxylic acid group, which makes van
der Waals interactions with the side chain of Phe54 and polar
interactions with other residues of the αAαB flap (Figure 6E). The
binding of the benzoxazepine derivatives causes significant con-
formational changes in the flap residues, widening the base of the
active site cavity.
The binding of zaragozic acid A (38) to hSQS has also been
characterized. As expected, the tricarboxylic acid core binds to the
PSPP pyrophosphate binding site, forming extensive H-bond and
electrostatic interactions with the αAαB flap residues as well as
Tyr73 and Arg77 (Figure 6F). The 4,6-dimethyloct-2-enoic acid
side chain occupies the donor FPP tail binding site, with interac-
tions similar to those described for the side chain of the substrate
analog 27, whereas the other side chain extends into the pre-
sumed NADPH binding site, making hydrophobic contacts with
the residues Phe54, Lue211, Pro292, Met295, and Ala296 (Liu
et al., 2012).
FUTURE DIRECTIONS IN DRUG DISCOVERY TARGETING THE HUMAN
PRENYL SYNTHASE ENZYMES FPPS, GGPPS, AND SQS
The human enzymes FPPS, GGPPS, and SQS occupy strate-
gic posts in modulating the levels of both down-stream and
up-stream metabolites derived from the mevalonate pathway.
These metabolites play an essential role in cell viability, sig-
naling and proliferation, and affect a plethora of biochemical
events that may impact human diseases from atherosclerosis to
dementia. An important concern about inhibiting targets with
such a large range of biochemical effects may be the poten-
tial of serious in vivo toxicities. This question can never be
answered without the discovery of selective inhibitors that allow
efficient in vivo investigations in animal models and clinical
studies. At this time, the clinical benefit of chronic inhibi-
tion of HMG-CoA reductase for the treatment of hypercholes-
terolemia is well established. Therefore, a therapeutic window
has been established between inhibiting the first control step
of the entire mevalonate pathway (i.e., inhibiting HMC-CoA
reductase) and reducing sufficiently the levels of all metabo-
lites, including cholesterol to achieve clinical benefits for patient
at high risk for cardiovascular diseases. Presumably, from a
mechanistic point of view, hSQS inhibitors can be as safe
and effective as HMG-CoA inhibitors in lowering cholesterol.
Similarly, inhibition of hFPPS (and consequently osteoclastic
activity) with compounds that target the bone tissue and have
limited systemic exposure is an established way of treating
lytic bone disease. However, it is still unknown whether effec-
tive treatment of non-skeletal cancers can be achieved with
hFPPS and/or hGGPPS inhibitors. A clear causative relation-
ship has yet to be established between up-regulation of iso-
prenoid biosynthesis and the progression (or initiation?) of
neurodegeneration in the Alzheimer’s diseases. Such important
biomedical questions can never be answered without the dis-
covery of molecular tools that specifically inhibit these prenyl
synthase enzymes in vivo and exhibit good exposure in non-
skeletal tissues, as well as permeability through the blood-brain
barrier.
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